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A b s t r a c t  
An attempt has been made to develop and optimize an novel anti hypertensive trilayered controlled 
release matrix tablets incorporated with Olmesartan medoxomil solid dispersion prepared by direct 
compression and consisted of middle active layer with different grades of hydroxypropyl 
methylcellulose (HPMC), guar gum, ethyl cellulose. Upper and lower layers are prepared with 
Carnauba wax, guar gum and sodium CMC. The developed drug delivery system provided 
prolonged drug release rates over a period of 24 h. The release profile of the optimized formulation 
(HF14) was described by the Zero-order and Higuchi model. In-vivo bioavailability studies were 
carried out with the optimized formulation (HF14) and reference standard A fair correlation between 
the dissolution profile and bioavailability for the optimized formulation was observed. The results 
indicate that the approach used could lead to a successful development of a trilayer extended 
release formulation up to 24h. These results also demonstrated that the Olmesartan solid dispersion 
incorporated trilayer tablets shown more bioavailability because of its conversion from crystalline to 
amorphous form. 
Keywords: Olmesartan medoxomil, Trilayer matrix tablet, Guar gum, Geomatrix, In-vivo 
bioavailability studies. 
Introduction 
Oral drug delivery has been known for decades as the most widely 
utilized route of administration among all the routes that have been 
explored for the systemic delivery of drugs via various 
pharmaceutical products of different dosage forms [1]. Controlled 
release pharmaceutical systems have been developed and studied 
to improve the performance of drugs and in particular to increase 
their pharmacological effect and reduce any side effects [2].  
A number of design options are available to control or modulate 
drug release from a drug delivery system. Most oral controlled 
release dosage forms fall in the category of matrix, reservoir or 
multi-layer systems. Lately, multi-layer matrix systems are gaining 
importance in the design of oral sustained drug delivery systems. A 
multi-layer system consists, usually, of a hydrophilic matrix core 
containing the active ingredient and one or two impermeable or 
semi-permeable polymeric coatings (barrier-layer) applied on one 
or both faces of the core during tabletting [3-5] 
The barrier layers delay the interaction of active solute with 
dissolution medium, by limiting the surface available for the solute 
release and at the same time controlling solvent penetration rate 
[6,7]. In the device, the coat layers prevent the water penetration 
through the protected core for some duration. After this phase 
during the subsequent dissolution process, the swollen barriers 
erode and the surface available for drug release slowly increases. 
In this way the decrease of delivery rate due to the increase in 
diffusion path length is counter balanced by the simultaneous 
increase of the area available for drug release [8,9] The use of 
naturally occurring biocompatible gums has been the focus of 
recent research activity in the design of dosage forms for oral 
controlled release administration, and hydrophilic polymers matrix 
systems are widely used because of their flexibility to provide a 
desirable drug release profile, cost effectiveness, and broad 
regulatory acceptance [10].  
There have been different approaches to achieve zero-order drug 
release from dosage forms for sustained plasma concentration. 
Among different approaches to achieve zero-order release from 
hydrophilic matrix technologies, multilayer matrices have been 
widely evaluated and developed for commercial products under the 
trade name of Geomatrix. The technology makes use of bilayer or 
trilayer tablets to modulate the release and to achieve constant 
release [11].  
Olmesartan Medoxomil is a non peptide angiotensin II receptor 
antagonist use in the treatment of mild to moderate hypertension. 
This drug is weakly basic, lipophilic and having very less oral 
bioavailability of about 26%. Olmesartan Medoxomil inhibits type I 
angiotensin II receptor in the rennin angiotensin system, there by 
producing best antihypertensive action [12].  
The main aim of the present study was to prepare Olmesartan solid 
dispersions to enhance its  water solubility as it belongs to BCS 
class II and bioavaibility (low bioavailability of 26%) and it was 





This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use  
and redistribution provided that the original author and source are credited. 




PAGE | 126 | 
 
 
different hydrophobic and hydrophilic polymers to achieve zero-
order drug release for sustained plasma concentration.  
 




Olmesartan pure drug was generous gift from Aurobindo Pharma 
Ltd., Hyderabad, India. Sodium carboxyl methyl cellulose, Ethyl 
cellulose, HPMC K 4 M, HPMC K & HPMC K 100 M was obtained 
from Rubicon labs, Mumbai. Guar gum was gifted from MSN Labs 




Formulation of controlled release Olmesartan trilayer 
matrix tablets 
 
The trilayered matrix tablets of Olmesartan were prepared by direct 
compression method. The first step in the formulation was to 
develop the middle active layer so as to give at least 90%drug 
release during 12hours. This layer would then be sandwiched 
between barrier layers (Upper & Lower layers) so as to continue 
the drug release for 24hours.   
 
Preparation of middle active layer  
 
Fourteen formulations (F1-F14) for active layer were formulated 
using polymers like different grades of HPMC (HPMC K14M & 
HPMC K100M) and Guar gum. All the formulations were varied in 
concentration of release retardant polymers and Olmesartan solid 
dispersions [13], talc (1.5mg) & magnesium stearate (1.5mg) 
constituted in all the formulations.  These materials were screened 
through ≠60 and mixed together in motor by using pestle. Final 
mixtures were compressed by using 12mm diameter flat punches 
on a sixteen station rotary tablet press where only one station was 
operative and other station were nullified Formulation F1-F14 
containing drug and other polymers prepared under condition as 
showed in table. 
 
Table 1: Formulation trails for active layer (F1-F7) 
INGREDIENTS (mg) F1 F2 F3 F4 F5 F6 F7 
Olmesartan Medoxomil (Solid 
dispersion)13 
160 160 160 160 160 160 160 
HPMC K 4 M 20 25 30 32 35 40 45 
HPMC K 100M --- --- --- ---- --- ---- ---- 
Ethyl cellulose 25 23 22 21 21 20 18 
Guar gum 15 15 10 12 12 09 09 
Sodium carboxy methyl cellulose 12 11 11 9 10 09 08 
Dibasic calcium phosphate 15 13 14 13 09 09 07 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
Table 2: Formulation trails for active layer (F8-F14) 
INGREDENTS (mg) F8 F9 F10 F11 F12 F13 F14 
Olmesartan medoxomil (SD) 160 160 160 160 160 160 160 
HPMC K 4M --- ---- ---- ---- ---- ---- ---- 
HPMC K 100M 25 30 35 37 40 45 49 
Ethyl cellulose 12 20 15 15 17 12 09 
Guar gum 09 12 16 11 9 15 10 
Sodium carboxy methyl cellulose 06 15 13 12 11 11 10 
Dibasic calcium phosphate 06 15 13 14 13 09 09 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
  




PAGE | 127 | 
 
 
Preparation of barrier layers 
 
The barrier layers (Upper & Lower layers) was formulated 
employing hydrophobic polymers Carnauba wax and Guar gum, 
which include water soluble DCP & EC. Composition of barrier 
layers was depicted in Table 3.  
The procedure tried to make the compacts was via direct 
compressions. For the first procedure the carnauba wax, xanthan 
gum and the filler was mixed in mortar and lubricated with 
magnesium stearate. The mix is then compressed using rotary 
press having 12mm flat tooling. 
 
Table 3: Formulation trails for barrier layer 
Ingredients (mg) A B C D E F G H 
Carnauba wax 5 10 15 20 25 30 35 40 
Guar gum 22 24 22 18 20 22 20 20 
Ethyl cellulose 20 16 20 17 18 10 12 12 
Dibasic calcium 
Phosphate 
50 47 40 42 34 35 30 25 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
Formulation of Olmesartan tryilayer tablets 
 
The powder mixtures required for active and barrier layers were 
weighed accurately and thoroughly mixed using mortar and pestle 
for about 20 minutes. Initially, the volume of die cavity (12mm, 
round) was adjusted equivalence to the weight of trilayered matrix 
tablets (450mg). Then the pre weighed amount of powder 
equivalent to bottom layer (100mg) was taken and placed in the die 
cavity and slightly compressed for uniform spreading. The upper 
punch was lifted up and 250mg of the drug containing middle active 
layer optimized formulation (F14) was placed over the bottom layer 
in the die cavity and again slightly compressed. The remaining 
volume of the die cavity was filled with pre weighed (100mg) 
amount of powder equivalent to top layer and compressed with the 
full force of compression on rotary tablets press to obtain tri-layered 
tablets. Tri-layered matrix tablets of each composition were 
compressed and tested for their friability, Hardness, drug content 
and drug release characteristics with a suitable number of tablets 
for each test. 
 
Table 4: Composition of Olmesartan trilayer matrix tablets 
INGREDIENTS (mg) AF14 BF14 CF14 DF14 EF14 FF14 GF14 HF14 
MIDDLE LAYER (F14) 
Olmesartan 160 160 160 160 160 160 160 160 
HPMC K 100M 49 49 49 49 49 49 49 49 
Ethyl cellulose 09 09 09 09 09 09 09 09 
Guar gum 10 10 10 10 10 10 10 10 
Sodium CMC 10 10 10 10 10 10 10 10 
Dibasic calcium 
phosphate 
09 09 09 09 09 09 09 09 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
BARRIER LAYER (on each side) 
Carnauba wax 5 10 15 20 25 30 35 40 
Guar gum 20 16 20 17 18 10 12 12 
Ethyl cellulose 22 24 22 18 20 22 20 20 
Dibasic calcium 
Phosphate 
50 47 40 42 34 35 30 25 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
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Evaluation of Olmesartan trilayer matrix tablets 
Weight variation, hhardness, thickness, ffriability were evaluated.  
 
Drug content / Assay 
20 tablets were accurately weighed and powdered.10mg equivalent 
powder was dissolved in 50ml distilled water and sonicated for 15 
minutes. It was filtered and washed with distilled water. Filtrate and 
washings were combined. Final volume was made up to 100ml with 
distilled water. Absorbance of this solution was determined in a UV 
spectrophotometer at 248nm. Amount of Olmesartan in tablets was 
calculated by using regression equation. 
 
In-vitro drug release profile 
In vitro drug release studies for developed Olmesartan trilayer 
matrix tablets were carried out by using dissolution apparatus II 
paddle type (Electrolab TDL-08L). The drug release profile was 
studied in 900ml Phosphate buffer pH 6.8 at 37± 0.50C 
temperature. The amount of drug release was determined by UV 
visible spectrophotometer (Shimadzu UV 1800) at 248nm. 
 
Drug release kinetics  
 
To describe the kinetics of the drug release from matrix tablet, 
mathematical models such as Zero-order, First order and Higuchi, 
models were used. The criterion for selecting the most appropriate 
model was chosen on the basis of the goodness-or fit test. 
 
Drug-excipient compatibility studies 
 
Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra for pure drug, physical mixture and optimized 
formulations were recorded using a Fourier transform Infrared 
spectrophotometer. The analysis was carried out in Shimadzu-IR 
Affinity 1 Spectrophotometer. The samples were dispersed in KBr 
and compressed into disc/pellet by application of pressure. The 
pellets were placed in the light path for recording the IR spectra. 
The scanning range was 400-4000 cm-1 and the resolution was 1 
cm-1. 
 
Pharmacokinetic study of Olmesartan medoxomil 
Animal Preparation  
Male rabbits were (weighing 2-3kg) selected for this study, all the 
animals were healthy during the period of the experiment. Animals 
were maintained at room temperature 250C, Relative Humidity 45% 
and 12h alternate light and dark cycle with 100 % fresh air 
exchange in animal rooms, uninterrupted power and water supply 
and rabbits were fed with standard diet and water ad libitum. The 
protocol of animal study was approved by the institutional animal 
ethics committee Vijaya College of Pharmacy, Munganoor, 
Hyathnagar, Rangareddy dist.(IAEC NO: 
P40/VCP/IAEC/2015/9/DBP/AE15/Rabbits). 
In vivo study design 
The rabbits were randomly divided into two groups each group 
contains six animals. The group A was received prepared 
Olmesartan matrix tablets (40mg), standard conventional tablets 
(40mg) was administered group B with equivalent dose of animal 
body weight. Blood samples (approximately 0.5ml) were obtained 
with syringes by marginal ear vein at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 
16, 20 and 24h post dose. During collection, blood sample has 
been mixed thoroughly with heparin in order to prevent blood 
clotting. Plasma was separated by centrifugation of the blood at 
5000rpm in cooling centrifuge for 5min to 10min and stored frozen 
at −20°C until analysis.  
 
Preparation of Plasma Samples for HPLC Analysis 
Rabbit plasma (0.5 ml) samples were prepared for chromatography 
by precipitating proteins with 2.5 ml of ice-cold absolute ethanol for 
each 0.5ml of plasma. After centrifugation the ethanol was 
transferred into a clean tube. The precipitate was re suspended 
with 1 ml of Acetonitrile by vortexing for 1 min. After centrifugation 
(5000 – 6000rpm for 10min), the Acetonitrile was added to the 
ethanol and the organic mixture was taken to near dryness by a 
steam of nitrogen at room temperature.  
 
HPLC Method 
C18 column with 5μm particle size and the Mobile Phase 
consisting of binary mixture of 10mM mixed phosphate buffer (pH 
3.0 ± 0.05) and methanol in a ratio of 40:60v/v. The flow rate was 
1.0ml/min and the effluents were monitored at 255nm. Internal 
standard Eprosartan was used. The retention times was 5.15min 
and 2.87min respectively Olmesartan and Eprosartan [14]. 
 
Pharmacokinetic analysis  
The pharmacokinetic parameters employed to evaluate were 
maximum plasma concentration (Cmax), time to attain Cmax i.e., 
Tmax and t ½ values, area under plasma concentration–time curve 
from zero to the last sampling time (AUC0-t), area under plasma 
concentration–time curve from zero to infinity (AUC0-∞). AUC0-t was 
calculated by the linear trapezoidal rule and AUC0-∞ from the 
following formula. 
 
AUC0-∞ = AUC0-t + Ct / KE 
 
Results and Discussion  
 
Preparation of Olmesartan active layer 
The matrix tablets of Olmesartan were prepared without the barrier 
layers by direct compression method. All the formulation trails were 
subjected to in vitro dissolution to determine the drug release 
profile.  
 













Figure 2: In vitro Dissolution profile of F8-F14 Olmesartan active layer formulations 
From the above results, the formulation F14 was decided as optimized formulation based on the highest drug release i.e. 
99.2±0.10 upto 12 h when compare with other formulations as active layer of the trilayer tablets. 
 
Table 5: Evaluation parameters of Olmesartan trilayer matrix tablets 




Weight  variation  
(mg) 
%Drug content 
AF14 4.64 6.6±0.23 0.27 448±12 98.4 
BF14 4.71 7.1±0.42 0.23 447±11 96.9 
CF14 4.54 7.4±0.41 0.25 448±16 97.2 
DF14 4.73 7.3±0.32 0.25 447±14 96.7 
EF14 471 7.4±0.59 0.28 448±11 98.8 
FF14 4.68 6.7±0.22 0.26 446±16 96.7 
GF14 4.55 7.6±0.55 0.24 448±13 98.4 
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The evaluation parameters of all the tablets are within the 
limits and the hardness ranges in between 6-7kg/cm2. The 
percentage drug content was between 96-99. The 
Friability, weight variation and thickness was found to be 
within the limits. Hence all the tablets were subjected to in 
vitro dissolution test to determine the release profiles. 
 
Table 6:  In-vitro  dissolution studies of Olmesartan trilayer tablets 
Time 
(h) 
AF14 BF14 CF14 DF14 EF14 FF14 GF14 HF14 
Reference 
standard 
1 12.34±0.01 14.16±0.01 16.21±0.04 18.22±0.04 19.22±0.04 20.85±0.04 20.47±0.05 21.02±0.04 96.01±0.06 
2 22.11±0.02 24.28±0.02 22.23±0.05 23.21±0.05 25.32±0.02 21.25±0.05 24.54±0.05 26.99±0.09  
4 32.15±0.13 33.38±0.34 34.28±0.05 36.32±0.04 36.35±0.03 37.23±0.45 38.43±0.05 39.23±0.03  
6 41.25±0.05 42.45±0.03 43.79±0.05 44.15±0.14 45.62±0.04 46.54±0.05 48.25±0.04 49.99±0.05  
8 51.16±0.19 52.98±0.094 53.23±0.05 55.42±0.08 56.32±0.05 57.15±0.04 58.45±0.02 59.99±0.07  
12 60.34±0.05 62.99±0.05 53.75±0.06 64.12±0.05 66.46±0.05 66.99±0.05 68.74±0.03 69.97±0.05  
16 69.75±0.43 72.55±0.11 73.68±0.26 75.24±0.24 76.53±0.14 78.32±0.01 78.65±0.03 79.99±0.05  
20 80.24±0.05 81.20±0.05 82.95±0.07 84.21±0.05 85.15±0.06 88.22±0.05 86.85±0.02 89.55±0.06  
24 86.12±0.04 90.24±0.03 93.45±0.01 91.22±0.02 93.55±0.04 94.24±0.04 95.25±0.02 98.56±0.19  
 
 
Figure 3: Comparison of Cumulative percentage drug release of Olmesartan trilayered matrix tablets and reference standard. 
 
The In vitro drug profile of Olmesartan from different formulations 
was carried and the results are depicted in Table 6 & Figure 3.  The 
trilayer tablets extended the drug release up to 24hrs. The highest 
drug release was found in the formulation HF14 i.e 98.56±0.19% 
within 24hrs. HF14 was found to be optimized formulation based on 
the dissolution and other evaluation parameters. The in vitro drug 
release profile from reference standard conventional tablet was 
found to be 96.01±0.06% within 60min. 
 
Release order kinetics of Olmesartan trilayer matrix 
tablets with reference standard 
 
In the present study drug release mechanism of Olmesartan trilayer 
matrix tablets are best fitting to zero order and Higuchi model 
because regression coefficient was seen closest to 1 in these 
models which conforms diffusion assisted mechanism of release. 
The reference standard release was explained by first order 
kinetics as the plot showed highest linearity as the drug release 
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Table 7: Release order kinetics of Olmesartan trilayer matrix tablets with reference standard. 
Formulation code Zero order 
       R2 
First order 
       R2 
Higuchi 
       R2 
Korsmeyer Peppas 
       R2 
Korsmeyer Peppas 
n value 
AF14 0.979 0.862 0.946 0.975 0.558 
BF14 0.980 0.863 0.947 0.976 0.604 
CF14 0.984 0.867 0.951 0.981 0.573 
DF14 0.982 0.865 0.949 0.979 0.634 
EF14 0.985 0.868 0.952 0.982 0.598 
FF14 0.987 0.869 0.954 0.983 0.721 
GF14 0.989 0.870 0.955 0.985 0.719 
HF14 0.991 0.871 0.957 0.987 0.695 
Reference standard 0.916 0.977 0.928 0.905 0.665 
 
Characterization FT-IR studies 
 
Figure 4:   FT-IR spectrum of pure drug Olmesartan medoxomil 
 
Figure 5:  FT-IR spectrum of physical mixture 








Figure 6:   FT-IR spectrum of optimized formulation HF14 
 
From FTIR spectrum there was no alteration in peaks of 
Olmesartan pure drug and optimized formulation, suggesting that 
there was no interaction takes place between drug & excipients. 
The FTIR spectrum of Olmesartan pure drug, with physical mixture 





Figure 7: Plasma Concentrations of Olmesartan Optimized formulation and Reference standard at different time intervals 
  
Table 8: Comparison of pharmacokinetic parameters of Olmesartan Optimized formulation and Reference standard 
 
Parameters Olmesartan Optimized formulation  Reference standard  
Cmax (ng/ml) 521.11±0.05 674.11±0.01 
AUC 0-t (ng h/ml) 7135.65±0.12 3523.25±0.02 
AUC0-∞ (ng h/ml) 8167.75±0.14 3945.14±0.02 
Tmax (h) 6.02±0.14 1.15±0.12 
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Mean plasma concentration profiles of prepared Olmesartan 
optimized formulation and marketed product are presented in 
Figure 7. Olmesartan optimized formulation exhibited as sustained 
release in vivo when compared with marketed tablet. All the 
pharmacokinetics parameters displayed in Table 8. In this study the 
prolonged drug absorption was achieved with the test formulation. 
The average peak concentration of the reference formulation was 
higher than that of the test (674.11±0.01ng/ml for the test 
formulation versus 521.11±0.05ng/ml for the reference). AUC is an 
important parameter in evaluating bioavailability of drug from 
dosage form, as it represents the total integrated area under the 
blood concentration time profile and represents the total amount of 
drug reaching the systemic circulation after oral administration. 
AUC0-inf for optimized formulation was higher (8167.75±0.14 ng 
h/ml) than the reference standard 3945.14±0.02ng h/ml. 
Statistically, AUC0-t of the optimized preparation was significantly 
higher (p<0.05) as compared to reference standard. Higher amount 
of drug concentration in blood indicated better systemic absorption 
of Olmesartan from optimized formulation as compared to the 
reference standard product.  
Summary and Conclusion 
All carnauba wax and guar gum formulations displayed sustained 
release with the Olmesartan incorporated solid dispersion trilayer 
matrix tablets, however three-layer tablet formulations 
demonstrated lower drug release compared to matrix tablets. 
Based on the evaluation parameters, drug dissolution profile and 
release drug kinetics HF14 was found to be optimized formulation. 
The drug release from HF14 was found to fit Zero order and best 
fitted to Higuchi’s model confirming to be diffusion assisted 
mechanism. FTIR studies revealed that, there was no interaction 
between the drug and polymers used in the formulations. In vivo 
bioavailability studies were conducted for optimized formulation 
HF14 and reference standard. The optimized formulation of 
Olmesartan trilayer matrix tablet was shown significant plasma 
concentration with controlled release and maintained for 24 hrs. 
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